Back to top
more

Gilead Sciences, Inc. (GILD)

(Delayed Data from NSDQ)

$68.01 USD

68.01
8,357,190

-1.19 (-1.72%)

Updated Nov 19, 2018 03:58 PM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.32%
18.25%
9.79%
5.22%
2.14%
10.57%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

A Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta

Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.

AZN GSK NVS GILD

Zacks Equity Research

Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension

Amgen's (AMGN) leukemia drug, Blincyto receives positive CHMP opinion for label expansion to include minimal residual disease.

PFE GILD AMGN ALXN

Zacks Equity Research

Biotech Stock Outlook: Approval of New Drugs to Boost Performance

While decline in sales of high-profile drugs and competitive pressure are likely to weigh on the biotech sector, we expect approval of new drugs to offset the impact of the same.

REGN GILD ALXN

Zacks Equity Research

Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC

Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.

MRK BMY RHHBY GILD

Zacks Equity Research

Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

JPM PFE GILD SGMO

Zacks Equity Research

Acorda Down More Than 30% in the Past 3 Months: Here's Why

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.

ACOR GILD ALXN MYL

Zacks Equity Research

BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%

BeiGene (BGNE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GILD BGNE

Zacks Equity Research

Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

SNY ZIOP GILD REGN COCP

Zacks Equity Research

Roche's Tecentriq Gets Priority Review for Breast Cancer

Roche's efforts to expand the label of its immuno-oncology drug Tecentriq advances as the FDA accepts its sBLA and grants priority review for the treatment of breast cancer.

NVS RHHBY AMGN GILD

Zacks Equity Research

Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.

GHDX GILD AMRN ALXN

Zacks Equity Research

Cronos (CRON) to Report Q3 Earnings: What's in the Offing?

Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.

BMY GILD TLRY CRON

Zacks Equity Research

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

BMY NVS GILD TLRY

Zacks Equity Research

Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus

The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.

GILD ALNY ALXN MDCO

Zacks Equity Research

Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

MRK BMY GILD ENDP

Zacks Equity Research

Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales

Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.

ARNA GILD ALXN SBPH

Zacks Equity Research

Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

PFE GILD AERI BHC

Zacks Equity Research

PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

ALXN PDLI BIIB GILD

Zacks Equity Research

Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3

Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.

RHHBY CELG PRTA GILD

Zacks Equity Research

Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates

Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3

JNJ ALXN GILD PCRX

Zacks Equity Research

Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down

Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.

RHHBY ALXN GILD PBYI

Zacks Equity Research

Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss

Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.

LLY GILD AMGN RDUS

Zacks Equity Research

Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock

Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.

AGIO CELG GILD CLBS

Zacks Equity Research

Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

SNY GSK GILD EBS

Zacks Equity Research

Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

NVS PFE CNAT GILD

Zacks Equity Research

bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

CELG REGN GILD BLUE